Back to results
US 2016/0168116 A1Published application
IRE-1alpha Inhibitors
AssigneeMannKind Corporation
InventorsJohn B. Patterson, David G. Lonergan, Gary A. Flynn, Qingpeng Zeng, Peter V. Pallai
Life of this patent
Estimating the term…
Abstract
Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
Claims20
A compound or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of structural formula (A):
- wherein:
- R1 is hydrogen, halogen, or a 5- or 6-membered heterocyclic containing one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- R2 is hydrogen,
- phenyl, or a 5- or 6-membered heterocyclic containing 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heterocyclic is optionally benzofused and wherein the heterocyclic is optionally substituted by 1, 2, or 3 substituents independently selected from
- C1-C3 linear or branched alkyl,
- C1-C3 phenylalkyl, C1-C3 alkoxyphenylalkyl,
- R3 is hydrogen, halogen, —NO2, C1-C3 linear or branched alkoxy, C1-C3 linear or branched hydroxyl alkyl,
- and
- Q is a five- or six-membered heterocycle.
6 more elements
Dependencies are inferred from the claim text.